Algaechen Biotech Secures Tens of Millions RMB in Angel Funding to Accelerate R&D and Industrialization of Microalgae-Based Synthetic Biology Derivatives

On March 1, Beijing Zaochen Biotechnology Co., Ltd. (hereinafter referred to as “Zaochen Biotech”) announced the completion of its angel-round financing, amounting to tens of millions of RMB. The round was led by Quanhua Life Sciences, and the funds will be used to build a research and development platform for microalgae synthetic biology derivatives and a pilot-scale production facility.

Beijing Zaochen Biotechnology Co., Ltd.Located in the Agricultural Zhongguancun Park, Yukou Town, Pinggu District, Beijing, Beijing Zaochen Biotechnology Co., Ltd. specializes in manufacturing innovative proteins and nutritional functional ingredients using microalgae biosynthesis technology. The company is committed to becoming a pioneer in transforming the microalgae industry from “agricultural” to “industrial” models, providing solutions for building a diversified food supply system and promoting the development of the nutrition and health industry in China.Leveraging Chief Scientist Professor Liu Bin’s over ten years of technical accumulation in the field of microalgae at Yantai University, the company has established a microalgae artificial evolutionary breeding platform, a high-throughput screening platform, and a genetic engineering modification platform in the area of germplasm resources. Through these efforts, it has obtained several superior algal strains, including Chlorella pyrenoidosa, Euglena gracilis, Schizochytrium sp., and diatoms. In terms of manufacturing technology, the company has innovated new high-efficiency, high-yield technologies for protein biosynthesis based on Chlorella pyrenoidosa and β-1,3-glucan biosynthesis based on Euglena gracilis. It has constructed an industry-leading key technology system for the biomanufacturing of microalgae-derived functional ingredients. The company has successfully achieved pilot-scale production and verified scalable manufacturing capabilities. The protein content of Chlorella pyrenoidosa can reach 60% of its dry weight, while the polysaccharide content of Euglena gracilis can reach 65% of its dry weight. Multiple invention patents have been granted in related fields.

Beijing Zaochen Biotechnology Co., Ltd. boasts a professional R&D team and an application support team, covering fields such as biotechnology, food science, human nutrition, and animal nutrition. The company has established strategic “industry-academia-research” collaborations with multiple universities, research institutes, and renowned platform institutions to jointly promote the development of microalgae synthetic biology. Targeting the human nutrition and health as well as animal nutrition and health industries, it has formed a commercialized matrix of microalgae products, including functional ingredients such as Euglena powder, Chlorella pyrenoidosa powder, and DHA algal oil, which exhibit excellent quality and functional characteristics. Leveraging these functional microalgae ingredients, the team has developed novel food products such as microalgae protein bars, microalgae protein-based meat analogs, and Euglena solid beverages.

Regarding this round of financing,Dr. Yang Yang, FounderHe stated, “We are honored that our angel round of financing has attracted interest from multiple institutions, and we are delighted to join forces with Quanhu Life Sciences to leverage our complementary strengths. Since its establishment in 2022, Zaochen Biotechnology has achieved rapid growth through the dedicated efforts of all employees, supported by the Pinggu District Agricultural Food Synthetic Biology Platform. Looking ahead, we believe the completion of this angel round will accelerate the translation of Zaochen Biotechnology’s innovative products from the laboratory to industrialization and commercialization, while also propelling the company’s technological capabilities to new heights.”

As the lead investor in this round of financing,QuanHua Life“We are impressed by Zaochen Biotechnology’s foundational technological innovation capabilities in the field of synthetic biology. Its proprietary high-throughput microalgae screening platform, gene-editing platform, and high-cell-density cultivation technology have not only broken through the efficiency bottlenecks of traditional manufacturing but also established differentiated competitive barriers in the functional ingredients and health food sectors. We are optimistic about the team’s execution capability in translating cutting-edge technologies into commercial value, particularly as its product pipeline—including Euglena gracilis and Chlorella pyrenoidosa—has achieved a critical leap from laboratory research to industrial-scale production. Following this round of financing, both parties will engage in deep collaboration on process optimization, channel deployment, and supply chain integration, jointly accelerating the rapid development of biomanufacturing technologies.”

Beijing Zaochen Biotechnology Co., Ltd. is located in the Agricultural Zhongguancun Park, Yukou Town, Pinggu District, Beijing. The company specializes in manufacturing innovative proteins and functional nutritional ingredients using microalgae biosynthesis technology, providing solutions for building a diversified food supply system and promoting the development of the nutrition and health industry in China.

Quanhua Life is an integrated innovation platform focused on biopharmaceuticals, medical devices, and life sciences. Guided by the core philosophy of “innovation-driven growth and full-chain empowerment,” the company provides healthcare enterprises with comprehensive, end-to-end solutions spanning research and development (R&D), manufacturing, and commercialization. Committed to delivering full-lifecycle support, Quanhua Life helps companies enhance operational efficiency, mitigate risks, and accelerate industrialization through joint incubation, industry empowerment, financial support, and management optimization. Currently, Quanhua Life has made strategic investments in numerous healthcare companies, building an innovative R&D ecosystem that covers the entire healthcare industry chain. Dedicated to advancing medical technology, the company strives to bring more high-quality products to market, benefit patients worldwide, and create long-term value for society.